GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hinova Pharmaceuticals Inc (SHSE:688302) » Definitions » EPS (Diluted)

Hinova Pharmaceuticals (SHSE:688302) EPS (Diluted) : ¥-2.14 (TTM As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Hinova Pharmaceuticals EPS (Diluted)?

Hinova Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was ¥-0.55. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥-2.14.

Hinova Pharmaceuticals's EPS (Basic) for the three months ended in Sep. 2024 was ¥-0.55. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥-2.13.

Hinova Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2024 was ¥-0.55. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was ¥-2.14.

During the past 3 years, the average EPS without NRIGrowth Rate was 24.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Hinova Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 24.70% per year. The lowest was 24.70% per year. And the median was 24.70% per year.


Hinova Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for Hinova Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hinova Pharmaceuticals EPS (Diluted) Chart

Hinova Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial - -6.97 -4.12 -3.32 -2.97

Hinova Pharmaceuticals Quarterly Data
Dec18 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.74 -0.57 -0.48 -0.54 -0.55

Competitive Comparison of Hinova Pharmaceuticals's EPS (Diluted)

For the Biotechnology subindustry, Hinova Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hinova Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hinova Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Hinova Pharmaceuticals's PE Ratio falls into.



Hinova Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Hinova Pharmaceuticals's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-294.158-0)/99.043
=-2.97

Hinova Pharmaceuticals's Diluted EPS for the quarter that ended in Sep. 2024 is calculated as

Diluted EPS (Q: Sep. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-53.659-0)/97.455
=-0.55

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-2.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hinova Pharmaceuticals  (SHSE:688302) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Hinova Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Hinova Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Hinova Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.

Hinova Pharmaceuticals Headlines

No Headlines